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The epithelial growth factor receptor (EGFR) family of receptor tyrosine kinases has been reported to have an active role in a
number of malignancies. Amplifications and overexpression of various EGFR family members, including EGFR, Her2, and ErbB3, have
been reported in epithelial ovarian cancer. Although anti-EGFR-targeted therapy has shown limited clinical activity in ovarian cancer
to date, a recent report suggests that activation of ErbB3, one of the members of the EGFR family, may support the growth and
proliferation of ovarian cancer cells and that ErbB3 may therefore serve as a potential therapeutic target in this disease. Here, we
review the EGFR family and the clinical experience with anti-EGFR family member-directed therapies in ovarian cancer to date.
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The epithelial growth factor receptor (EGFR; also known as Her or
ErbB) family of receptor tyrosine kinases has been shown to have
oncogenic roles in a number of human cancers. Epithelial growth
factor receptor family-directed therapies have demonstrated
significant clinical activity in EGFR mutant lung cancers and
Her2-amplified breast cancers. Recent reports have suggested that
members of the EGFR family, such as ErbB3, may have a role in
supporting the growth and proliferation of human ovarian cancer
cells. Epithelial ovarian cancer remains a leading cause of death in
women, with an estimated 204000 cases and 125000 deaths
worldwide (Parkin et al, 2005). Here, we review the reported
biology and clinical experience with EGFR family-directed
therapies in epithelial ovarian cancer.
STRUCTURE AND SIGNALLING OF EPITHELIAL
GROWTH FACTOR RECEPTOR FAMILY MEMBERS
The EGFR family of receptor tyrosine kinases consists of four
closely related family members: EGFR (Her1), ErbB2 (Her2), ErbB3
(Her3), and ErbB4 (Her4; Yarden, 2001). Throughout this review,
these kinases shall be referred to as EGFR, Her2, ErbB3, and ErbB4.
These cytoplasmic membrane-bound receptors share a common
extracellular ligand-binding domain and a single transmembrane
domain, followed by an intracellular tyrosine kinase domain and a
C-terminal non-catalytic signalling tail. Signalling through these
receptors is typically mediated by homodimerisation or hetero-
dimisation with other family members. With the exception of
Her2, the extracellular domains of the EGFR family members
prevent the formation of stable heterodimers or homodimers in
the absence of the ligand (Ogiso et al, 2002). Binding of the ligand
with the extracellular domain of its corresponding receptor
induces a structural reconfiguration of the receptor, promoting
exposure of the otherwise tethered dimerisation domain
(Ogiso et al, 2002). This, in turn, leads to stabilisation of receptor
dimers. Dimerisation results in asymmetric kinase activation,
transphosphorylation, and induction of downstream signalling
pathways. The EGFR family members can also be activated by
ligand-independent activation (Siwak et al, 2010). These mechan-
isms include activation by unphysiological stimuli (e.g., oxidative
stress, UV, and g-irradiation), by other receptor tyrosine kinases
(notably MET, insulin-like growth factor-1 receptor, or tyrosine
kinase receptor B), or by G protein-coupled receptors and
adhesion proteins.
The importance of dimerisation in EGFR family signalling is
best illustrated by Her2 and ErbB3. Her2 is the preferred
dimerisation partner for all of the EGFR family members (Tzahar
et al, 1996). However, although Her2 has the strongest kinase
activity among the family members, there is no known ligand to
this receptor. Consequently, activation of Her2 is dependent upon
dimerisation with other family members. In contrast, ErbB3 can be
bound by at least two known ligands, but lacks intrinsic kinase
activity and is therefore dependent upon heterodimerisation to
phosphorylate its signalling tail and mediate downstream signal-
ling effects. Interestingly, these so called ‘deaf and dumb’ members
of the EGFR family form the most potent transforming unit among
all of the possible dimerisation units (Tzahar et al, 1996).
Multiple ligands are known to bind to the EGFR family. Some
of these ligands bind specifically to EGFR (EGF, TGF-a,a n d
amphiregulin) or ErbB4 (neuregulin 3, neuregulin 4, and tomo-
regulin), whereas others have dual specificity (e.g., b-cellulin,
epiregulin, and heparin-binding EGF-like growth factor for both
EGFR and ErbB4, and neuregulins 1 and 2 for both ErbB3 and ErbB4;
Normanno et al, 2006). Various expression levels of these ligands
have been detected in both ovarian cancer cell lines and primary
ovarian tumour samples (Lafky et al, 2008).
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signalling molecules through the phosphorylated cytoplasmic
domain, which further leads to activation of a variety of
downstream signalling pathways (reviewed by Normanno et al,
2006). All of the EGFR family members activate the extracellular
signal-regulated kinase (Erk)1/2 via recruitment of Grb2 or Shc
adaptors. Activation of Erk1/2 has an important role in EGFR-
stimulated cell proliferation. Activation of another important
signalling pathway for cell proliferation and survival, the
phosphatidylinositol 3-kinase (PI3K)/Akt pathway, however,
differs between the EGFR family members. Whereas ErbB3 and
ErbB4 are capable of binding the p85 regulatory subunit of PI3K
directly through their putative p85 binding sites (tyrosine-X-X-
methionine), EGFR and Her2 bind indirectly to p85 through
adaptors or through heterodimerisation with ErbB3 or ErbB4.
In addition to Erk1/2 and PI3K activation, phosphorylated
EGFR family members can also activate a collection of transcrip-
tion factors such as c-fos, c-jun, c-myc, signal transducer and
activator of transcription, NF-kB, zinc-finger transcription factor,
and Ets family members.
EPITHELIAL GROWTH FACTOR RECEPTOR/HER2
IN OVARIAN CANCER
A recent review by Siwak et al (2010) provides a comprehensive
update on the role of EGFR in ovarian cancer and the experience
with EGFR-targeted therapies in this disease. Epithelial growth
factor receptor amplification and activating mutations have been
reported in a small percentage of ovarian cancer cases (4–22% and
o4%, respectively). The EGFR overexpression rate varies from 9–
62%, depending on the antibody, the assay, and the cutoff
standard. Increased EGFR expression has been correlated with
poorer patient outcomes. Several small molecule inhibitors that
block EGFR kinase activity (e.g., gefitinib and erlotinib) have been
explored in the clinical setting. There are two phase II clinical trials
on gefitinib (Iressa or ZD1839) as a single agent in treating
platinum-refractory or -resistant ovarian cancer. No complete
response was observed in either trial. In one trial, 37% of the
patients had stable disease for over 2 months while none of the
patients had a partial or complete response. In the second trial,
4 out of 27 patients had progression-free disease for over 6 months
and one of these four patients had an objective response. Of note,
tumour samples from the patient who experienced a partial
response demonstrated a mutation in the EGFR kinase domain.
In this trial, EGFR expression was also evaluated by immunohis-
tochemistry, and a correlation between EGFR expression and
longer progression-free and overall survival was suggested
(P¼0.008 and P¼0.08, respectively). A phase II study combining
gefitinib and tamoxifen also demonstrated limited activity in
patients with platinum-refractory or -resistant ovarian cancer. Of
note, these trials were performed in an unselected patient
population. Erlotinib (Tarceva, OSI Pharmaceuticals, Long Island,
NY, USA), another small molecule inhibitor of EGFR, demon-
strated a 6% partial response rate in a multicentre phase II trial
with EGFR-positive ovarian cancer patients with taxane- and/or
platinum-refractory or -resistant disease.
Trials of EGFR-targeted agents with cytotoxic chemotherapy or
other targeted therapies have also been conducted. In a separate
phase I trial, when erlotinib was administered in conjunction with
docetaxel and carboplatin in 48 patients, a slightly lower response
rate was reported than in a historical control with docetaxel and
carboplatin alone (52 vs 59%; Siwak et al, 2010). More recently, a
phase II study of 56 patients demonstrated no improvement in
pathological CR rates compared with historical experience with
erlotinib added to carboplatin and paclitaxel in the first-line
therapy for ovarian cancer (Blank et al, 2010). Tumour specimens
were analysed for EGFR amplification in 20 patients, but
no statistically significant correlation was observed between
amplification status and response. An additional study comparing
the combination of erlotinib and the anti-angiogenic agent
bevacizumab also did not show any improvement compared with
bevacizumab alone. Similarly, vandetanib, a small molecule
inhibitor of VEGFR and EGFR signalling, did not demonstrate
significant clinical benefit in recurrent ovarian cancer (Annunziata
et al, 2010). In addition to small molecule inhibitors, monoclonal
antibodies that bind directly to the extracellular domain of EGFR
to block EGFR activation or reduce surface EGFR levels have also
been tested in clinic. The clinical activity of these therapeutic
antibodies, such as cetuximab (Erbitux, ImClone LLC,
Bridgewater, NJ, USA) and matuzumab (EMD7200), in ovarian
cancer appears to be very limited (Siwak et al, 2010).
Data regarding Her2 overexpression and its association with
prognosis in ovarian cancer are controversial. Early studies
suggested that Her2 overexpression in ovarian cancer was a
frequent event; however, most recent studies using techniques
validated in breast cancer suggest that Her2 overexpression and
amplification frequency in ovarian cancer is, in fact, a much rarer
event (Farley et al, 2009). Overexpression of Her2 has been
associated with a worse prognosis in some studies but not others.
This discrepancy may be in part explained by differences in the
criteria and methods used to assess Her2 overexpression.
Clinically, anti-Her2-directed therapies have not demonstrated
significant promise as therapeutic agents in ovarian cancer.
A phase II trial with trastuzumab (Herceptin, Genentech, Inc.,
South San Francisco, CA, USA), a humanised anti-Her2 mono-
clonal antibody, which has been used to successfully treat Her2-
overexpressing breast cancer, reported a low (7%) partial response
rate with only a 2-month progression-free interval in recurrent
ovarian cancers overexpressing Her2 (Bookman et al, 2003).
Reagents targeting multiple EGFR family members simulta-
neously have also been tested for their clinical activity in ovarian
cancer. In a phase II multicenter open-label trial, CI-1033
(Canertinib, Pfizer, Inc., New York City, NY, USA), an irreversible
pan-EGFR family inhibitor, was shown to have no activity in
unscreened patients who have failed previous platinum-based
chemotherapy (Campos et al, 2005). In this trial, the expression of
EGFR family members was also examined by IHC in archival
tumours and there was no association of EGFR family member
expression level and clinical outcome. A phase I trial combining
carboplatin and lapatinib (Tykerb, Tyverb, Glaxo SmithKline, plc,
London, UK), an EGFR-Her2 dual inhibitor, was performed in
unscreened patients with platinum-sensitive recurrent ovarian
cancer (Kimball et al, 2008). Three out of eleven (27%) patients
had a partial response and three patients (27%) had stable disease.
However, given significant non-dose limiting toxicities, including
grade 3 neutropenia and grade 4 thrombocytopenia, significant
treatment delays, and minimum clinical benefit, the authors did
not feel that this treatment regimen could be recommended for
further exploration.
ERBB3 IN OVARIAN CANCER
ErbB3 has been reported to be amplified (Tsuda et al, 2004) and
overexpressed in epithelial ovarian cancers (Simpson et al, 1995;
Tsuda et al, 2004; Tanner et al, 2006; Lafky et al, 2008; Sheng et al,
2010). In certain studies, overexpression of ErbB3 has been
reported to correlate with poorer overall prognosis (Tanner et al,
2006). In addition to full-length ErbB3, several truncated ErbB3
isoforms composed of the extracellular domains of the protein
have also been previously described in ovarian cancer cell lines,
but the functional significance of these remains unclear (Lee and
Maihle, 1998).
ErbB3 has been recently characterised as having a significant
role in mediating resistance to EGFR- and Her2-directed therapies
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in gefitinib-resistant Her2-overexpressing breast cancer cell lines,
ErbB3 activation is increased, potentially through increased
localisation of ErbB3 to the cytoplasmic membrane. In a separate
report, Engelman et al (2007) demonstrated that ErbB3 activation
by MET amplification could overcome resistance to gefitinib in
EGFR-mutant non-small-cell lung cancer cell lines. Most recently,
inhibition of AKT has been demonstrated to upregulate ErbB3
expression and phosphorylation, suggesting that ErbB3 may also
have a role in mediating resistance to PI3K/AKT pathway
inhibitors (Chandarlapaty et al, 2011).
A humanised monoclonal antibody that binds to the extra-
cellular domain of Her2 and blocks its heterodimerisation with
ErbB3 and other EGFR family members, pertuzumab (2C4), has
been explored in clinical trials in ovarian cancer. As a single agent,
pertuzumab treatment demonstrated only a 4.3% partial response
in platinum-refractory and -resistant patients. Her2 phosphoryla-
tion (pHer2) status in 28 of these patients with biopsiable disease
(out of a total of 55 patients) was assayed, with eight tumours
demonstrating positivity for pHer2 by an ELISA assay. ErbB3
status was not assessed in this trial. The median progression-free
survival in the eight pHer2þ patients was 20.9 weeks as compared
with 5.8 weeks in the pHer2  patients (P¼0.14), and the
possibility was raised that response to pertuzumab might be
linked to the presence of pHer2 as opposed to overexpression of
the protein (Gordon et al, 2006). A clinical trial has also been
conducted exploring the combination of pertuzumab with
gemcitabine vs gemcitabine alone (Makhija et al, 2010). In this
trial, no significant difference was seen in the outcome between the
two arms. However, a subset analysis demonstrated a potential
benefit in progression-free survival to gemcitabine plus pertuzu-
mab in patients with low ErbB3 expression by mRNA (hazard ratio
0.32; 95% CI 0.17–0.59; P¼0.0002).
More recently, signalling through the ErbB3 pathway has been
reported to correlate with expression of its natural ligand,
neuregulin-1 (NRG1) in both ovarian cancer cell lines and in
primary human ovarian cancer cells (Sheng et al, 2010).
Expression of NRG1 has been observed in 30–83% of ovarian
carcinomas (Gilmour et al, 2002; Sheng et al, 2010). Furthermore,
in a subset of ovarian cancer cells that display an NRG1-
expressing/phosphorylated-ErbB3 phenotype, depletion of ErbB3
by RNA interference (RNAi) could result in anti-proliferative
effects in vitro. In a mouse model of human ovarian cancer,
depletion of ErbB3 by RNAi reduced tumour growth and
prolonged mouse survival, while treatment with a monoclonal
anti-ErbB3 antibody (MM-121, Merrimack Pharmaceuticals,
Cambridge, MA, USA) also resulted in inhibition of tumour
progression (Sheng et al, 2010). Clinically applicable therapeutic
anti-ErbB3 antibodies, including MM-121 and U3-1287 (Amgen,
Thousand Oaks, CA, USA), are currently being tested in phase I
trials in solid tumours (http://www.clinicaltrials.gov). Their
potential activity as single agents or in combination with
additional cytotoxic or biological therapies in ovarian and other
cancers is currently an area of active interest and exploration.
ERBB4 IN OVARIAN CANCER
Among different EGFR family members, the role of ErbB4 in
cancer is probably the least understood. Conflicting reports
regarding the potential transforming activity of ErbB4 have been
published, which may partly reflect the unique mechanism of
ErbB4 signalling. Unlike the other EGFR family members, ErbB4 is
spliced into multiple isoforms, some of which are further
processed by tumour necrosis factor-a converting enzyme and
g-secretase to generate a soluble ErbB4 intracellular domain that
has a BH3 homologous region that can distribute to both the
nucleus and the cytoplasm (reviewed by Jones, 2008). Nuclear-
localised ErbB4 intracellular domain may act as a transcription
coactivator whereas the cytoplasmic/mitochondria-localised ErbB4
intracellular domain may act as a BH3-only protein and induce
apoptosis in tumour cells (Jones, 2008). In breast cancer,
cytoplasmic but not nuclear localisation of the ErbB4 intracellular
domain independently predicted for improved patient survival
(Jones, 2008). Clinically, ErbB4 somatic mutations have been
detected in 19% of melanoma patients (Prickett et al, 2009) and in
a variety of other cancer types although at a much lower frequency
(1–5%; reviewed by Rudloff and Samuels, 2010). In vitro
depletion of ErbB4 in some melanoma cell lines expressing
mutated ErbB4 inhibited proliferation, suggesting that mutated
ErbB4 may be an addicting oncogene in these particular cells
(Prickett et al, 2009).
ErbB4 is weakly expressed in adult ovarian surface epithelium
(Srinivasan et al, 1998). Although early studies suggested that
ErbB4 expression is either absent or decreased in some ovarian
cancers when compared with normal ovarian tissues (Scoccia et al,
1998; Srinivasan et al, 1998), recent investigations using either
IHC, RT–PCR, or western blotting techniques have demonstrated
the presence of ErbB4 in a high percentage of ovarian tumours
(Gilmour et al, 2001; Pejovic et al, 2009), and RT–PCR has
detected at least four different ErbB4 splice variants in both
established and primary ovarian cancer cell lines (Gilmour et al,
2001). Cytoplasmic staining of ErbB4 was detected in 89–93%
of 53 unselected ovarian cancer tumours using two different
anti-ErbB4 antibodies directed to either the cytoplasmic or the
extracellular domain of ErbB4 (Gilmour et al, 2001). In a more
recent study, as many as 96% of tumours (195 of 202) had
cytoplasmic, nuclear, and/or membranous ErbB4 staining (Pejovic
et al, 2009). Gilmour et al (2001) reported that tumours of serous
histology tend to express higher levels of ErbB4 than that of the
endometrioid subtype, and Steffensen et al (2008) found that
ErbB4 expression is significantly higher in epithelial ovarian
cancer tumours as compared with borderline/benign ovarian
tumours or normal ovaries. Somatic mutations in the intronic
regions of ErbB4 have been detected in ovarian cancers; however,
no mutations similar to that found in melanoma have been
reported thus far (Pejovic et al, 2009).
The clinical significance of ErbB4 in ovarian cancer is currently
unknown. Interestingly, established ovarian cancer cell lines that
Table 1 Summary of EGFR family members
EGFR
family
member Ligand(s)
Validated clinical
target in
non-ovarian
cancers
Characteristics
in ovarian
cancer
EGFR EGF Non-small-cell 4–22% Amplification
TGF-a Lung cancer o4% Mutation
Amphiregulin Colorectal
b-cellulin Head and neck
Epiregulin Pancreatic
HB-EGF
Her2 None Breast Rare (5–10%)
amplification/
overexpression
ErbB3 Neuregulin 1 Expression/amplification in
Neuregulin 2 3–90%
ErbB4 Neuregulin 1 Expression by IHC in
Neuregulin 2 89–96%
Neuregulin 3
Neuregulin 4
Tomoregulin
b-cellulin
Epiregulin
HB-EGF
Abbreviations: EGFR¼epithelial growth factor receptor; HB-EGF¼heparin-binding EGF-
like growth factor; IHC¼immunohistochemistry; TGF-a¼transforming growth factor-a.
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platinum-refractory tumours, raising the possibility that ErbB4
expression may associate with the development of platinum
resistance (Gilmour et al, 2001). On the other hand, an ErbB4
antibody that blocks ErbB4 and NRG1 interaction appeared to
have a stimulatory effect in some of the ovarian cancer cell lines
tested, suggesting a possible role for ErbB4 in growth inhibition in
these cells (Gilmour et al, 2001). Furthermore, higher ErbB4
expression has been reported to associate with improved disease-
free survival in ovarian cancers (Pejovic et al, 2009). Together,
these observations suggest that the role of ErbB4 in ovarian
tumours may be complicated and, to date, its function in both
early ovarian cancer development and late-stage disease remains
undefined.
CONCLUSION
The EGFR family of receptor tyrosine kinases remains of significant
interest in ovarian cancers. A summary of the characteristics of
this family is found in Table 1. Amplifications, mutations, and
overexpression of EGFR family members have been described in
epithelial ovarian cancer, and pre-clinical data have suggested that
interfering with the signalling activity of these pathways in ovarian
cancer cells can result in antitumour activity. Although EGFR- and
Her2-directed therapies have yielded disappointing clinical results to
date, recent reports regarding the role of other members of this
receptor tyrosine kinase family, such as ErbB3 and ErbB4, in ovarian
cancer suggest that new approaches towards targeting the EGFR
family merit further exploration.
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